Embecta (NASDAQ:EMBC) versus QHSLab (OTCMKTS:USAQ) Head-To-Head Contrast

Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for Embecta and QHSLab, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0	1	1	0	2.50
QHSLab	0	0	0	0	0.00

Embecta presently has a consensus price target of $23.00, suggesting a potential upside of 17.89%. Given Embecta’s stronger consensus rating and higher possible upside, analysts clearly believe Embecta is more favorable than QHSLab.

Profitability

This table compares Embecta and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	6.97%	-18.54%	11.43%
QHSLab	-3.24%	N/A	-3.43%

Risk & Volatility

Embecta has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, QHSLab has a beta of -0.82, indicating that its stock price is 182% less volatile than the S&P 500.

Valuation and Earnings

This table compares Embecta and QHSLab”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.12 billion	1.01	$78.30 million	$1.35	14.45
QHSLab	$1.41 million	1.35	-$470,000.00	($0.01)	-18.00

Embecta has higher revenue and earnings than QHSLab. QHSLab is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.8% of Embecta shares are owned by institutional investors. 0.3% of Embecta shares are owned by company insiders. Comparatively, 74.2% of QHSLab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Embecta beats QHSLab on 11 of the 14 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.